Nexxus Awards ceremony.

 

 

Nexxus Awards ceremony.

 

 

Nexxus Awards ceremony.

 

 

 

 

 

 

Vitrology News

Vitrology new star of Scottish life sciences

From the Scotsman Journal - 13 November 2008

VITROLOGY, a Glasgow-based drug testing firm, was last night named as Scotland's "most promising young life science company".

The firm, which was set up in April 2007 and has already attracted 20 experienced staff, was given the prize by Nexxus, the West of Scotland Bioscience Network….… Laura Gordon, Director of the Glasgow-Edinburgh Collaboration and keynote speaker at the awards, said: "Life sciences is one of Scotland's true success stories, with Glasgow and Edinburgh home to 360 companies, employing more than 24,000 people in the industry."As these awards have showcased, our native talent can compete on a global level."

Vitrology is delighted to win the Award. Dr Archie Lovatt, Scientific Director, collected the award on behalf of the company said :

"It's wonderful to receive this recognition of our achievements to date and validation of our hopes for the future”  

"Many international clients have approached us. We currently have contracts in place with a large number of companies in Europe and the USA, with several more about to be finalised.   Good Laboratory Practice (GLP) accreditation from the MHRA was received earlier this year and last month we were accredited with Good Manufacturing Practice (GMP) compliance.   This allows us to provide enhanced quality standards to meet increasing market demands, with a validated service offering increasing in size quarter by quarter.   We're just delighted with the way things are going and winning this Award is just the icing on the cake."

For more information please see: http://www.nexxusscotland.com/news/award_ology

 

Further success for Vitrology

22 September 2008

Following receipt of a Good Laboratory Practice (GLP) accreditation from the MHRA in March 2008, Glasgow based Vitrology - a biopharmaceutical Contract Research Organisation (CRO) - are pleased to announce they have had a successful Good Manufacturing Practice Compliance (cGMP) Inspection from the MHRA also. The successful outcome of the cGMP compliance inspection will allow them to implement GMP testing compliance for lot release, thus offering enhanced quality standards to meet increasing market demands.

The organisation's GLP/cGMP dedicated facility has been custom designed specifically for pre-clinical, clinical and production cell bank/viral vaccine testing, and the batch release testing of biopharmaceutical products intended for human and veterinary use. An extensive - and expanding - range of validated microbiological, molecular biology and virology assays is on offer to clients.

In addition, the company will provide an online BioNet integrated into their Client Relationship Management system, to allow clients and scientists to download and upload information, as it becomes available; interrogate data, for both ongoing and historical work; manage the flow of work without burdening the organisation with inefficient practices and put information "at the fingertips" of the scientists and clients involved.

GLP and cGMP compliance are vital in biopharmaceutical safety testing. To satisfy Regulatory Authorities such as the US Food and Drug Administration (FDA) and the European Medicines Evaluation Agency (EMEA), all cell banks, viral banks, raw materials of animal origin, bulk harvests and clinical drug products, must undergo extensive safety testing to show they are free from bacteria, fungi, Mycoplasma and viruses. Vitrology's state-of the-art laboratories and systems provide testing solutions in all of these areas.

In recent months the company has expanded its workforce to 20 and remains focused on increasing its market share and expanding its services for new biological therapeutics and vaccines.

For further information T: 0141 952 0022, E : info@vitrologybiotech.com.

 

Facility Project Completed

January 2008

In January this year, Vitrology completed the construction of their GLP/cGMP facility and started their contract testing services for the global biopharmaceutical industry. In March this year, the company was inspected and accepted into the Good Laboratory Practice (GLP) program of the UK Medical and Healthcare product Agency (MHRA). Vitrology was also inspected and accepted by the Health and Safety Executive (HSE) with regard to practices involving biological containment level 2. Vitrology has an ongoing assay development and validation master plan, and in February this year launched numerous real-time PCR assays for the quantification of residual host cell DNA. These services are the first to be available, with several product launches planned throughout 2008. Our aim is to ensure that the constant demands can be met for the safety testing of biopharmaceutical drugs and the treatment of human diseases.


 
Back Up.
 
© Vitrology 2008 All Rights Reserved